nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—CYP1A2—Carmustine—brain cancer	0.165	0.257	CbGbCtD
Pomalidomide—PTGS2—Etoposide—brain cancer	0.129	0.202	CbGbCtD
Pomalidomide—CYP3A4—Temozolomide—brain cancer	0.124	0.194	CbGbCtD
Pomalidomide—CYP3A4—Lomustine—brain cancer	0.106	0.165	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—brain cancer	0.0488	0.0761	CbGbCtD
Pomalidomide—ABCB1—Etoposide—brain cancer	0.0427	0.0665	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—brain cancer	0.0256	0.0399	CbGbCtD
Pomalidomide—Thalidomide—CYP2C9—brain cancer	0.0056	1	CrCbGaD
Pomalidomide—Febrile neutropenia—Carmustine—brain cancer	0.00296	0.0109	CcSEcCtD
Pomalidomide—Febrile neutropenia—Temozolomide—brain cancer	0.00286	0.0106	CcSEcCtD
Pomalidomide—Deep vein thrombosis—Temozolomide—brain cancer	0.00283	0.0105	CcSEcCtD
Pomalidomide—Embolism—Temozolomide—brain cancer	0.00268	0.0099	CcSEcCtD
Pomalidomide—Neuropathy—Procarbazine—brain cancer	0.00267	0.00987	CcSEcCtD
Pomalidomide—Pancytopenia—Lomustine—brain cancer	0.00267	0.00987	CcSEcCtD
Pomalidomide—Interstitial lung disease—Carmustine—brain cancer	0.00251	0.0093	CcSEcCtD
Pomalidomide—Renal failure—Lomustine—brain cancer	0.00246	0.00911	CcSEcCtD
Pomalidomide—Interstitial lung disease—Temozolomide—brain cancer	0.00243	0.00898	CcSEcCtD
Pomalidomide—Febrile neutropenia—Etoposide—brain cancer	0.00229	0.00846	CcSEcCtD
Pomalidomide—Interstitial lung disease—Etoposide—brain cancer	0.00194	0.00719	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Temozolomide—brain cancer	0.00189	0.00699	CcSEcCtD
Pomalidomide—Infection—Carboplatin—brain cancer	0.00181	0.00671	CcSEcCtD
Pomalidomide—Pulmonary embolism—Carmustine—brain cancer	0.00178	0.00658	CcSEcCtD
Pomalidomide—Leukopenia—Lomustine—brain cancer	0.00175	0.00648	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Temozolomide—brain cancer	0.00174	0.00644	CcSEcCtD
Pomalidomide—Pulmonary embolism—Temozolomide—brain cancer	0.00172	0.00636	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Carmustine—brain cancer	0.00172	0.00635	CcSEcCtD
Pomalidomide—Pancytopenia—Procarbazine—brain cancer	0.00169	0.00627	CcSEcCtD
Pomalidomide—Neuropathy—Carmustine—brain cancer	0.00167	0.00618	CcSEcCtD
Pomalidomide—CRBN—telencephalon—brain cancer	0.00166	0.0778	CbGeAlD
Pomalidomide—Depressed level of consciousness—Temozolomide—brain cancer	0.00166	0.00614	CcSEcCtD
Pomalidomide—Neuropathy—Temozolomide—brain cancer	0.00161	0.00597	CcSEcCtD
Pomalidomide—Pneumonia—Procarbazine—brain cancer	0.0016	0.00592	CcSEcCtD
Pomalidomide—Infection—Lomustine—brain cancer	0.00159	0.00587	CcSEcCtD
Pomalidomide—Thrombocytopenia—Lomustine—brain cancer	0.00156	0.00579	CcSEcCtD
Pomalidomide—Pain—Carboplatin—brain cancer	0.00156	0.00578	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Procarbazine—brain cancer	0.00156	0.00577	CcSEcCtD
Pomalidomide—Sepsis—Carmustine—brain cancer	0.00154	0.00571	CcSEcCtD
Pomalidomide—Epistaxis—Procarbazine—brain cancer	0.0015	0.00555	CcSEcCtD
Pomalidomide—Blood creatinine increased—Hydroxyurea—brain cancer	0.0015	0.00553	CcSEcCtD
Pomalidomide—Body temperature increased—Carboplatin—brain cancer	0.00144	0.00534	CcSEcCtD
Pomalidomide—Breast disorder—Hydroxyurea—brain cancer	0.00144	0.00534	CcSEcCtD
Pomalidomide—Decreased appetite—Lomustine—brain cancer	0.00139	0.00514	CcSEcCtD
Pomalidomide—CRBN—gonad—brain cancer	0.00139	0.0649	CbGeAlD
Pomalidomide—CRBN—pituitary gland—brain cancer	0.00135	0.0633	CbGeAlD
Pomalidomide—Pancytopenia—Hydroxyurea—brain cancer	0.00131	0.00485	CcSEcCtD
Pomalidomide—CRBN—medulla oblongata—brain cancer	0.00131	0.0611	CbGeAlD
Pomalidomide—Hyponatraemia—Carmustine—brain cancer	0.0013	0.0048	CcSEcCtD
Pomalidomide—Neuropathy—Etoposide—brain cancer	0.00129	0.00478	CcSEcCtD
Pomalidomide—Neutropenia—Hydroxyurea—brain cancer	0.00129	0.00477	CcSEcCtD
Pomalidomide—Chills—Procarbazine—brain cancer	0.00128	0.00474	CcSEcCtD
Pomalidomide—Body temperature increased—Lomustine—brain cancer	0.00126	0.00467	CcSEcCtD
Pomalidomide—Weight increased—Hydroxyurea—brain cancer	0.00126	0.00465	CcSEcCtD
Pomalidomide—Infestation—Hydroxyurea—brain cancer	0.00123	0.00455	CcSEcCtD
Pomalidomide—Infestation NOS—Hydroxyurea—brain cancer	0.00123	0.00455	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Hydroxyurea—brain cancer	0.00121	0.00446	CcSEcCtD
Pomalidomide—Sepsis—Etoposide—brain cancer	0.00119	0.00441	CcSEcCtD
Pomalidomide—CRBN—midbrain—brain cancer	0.00119	0.0559	CbGeAlD
Pomalidomide—Hypokalaemia—Carmustine—brain cancer	0.00118	0.00435	CcSEcCtD
Pomalidomide—Tremor—Procarbazine—brain cancer	0.00116	0.00431	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Hydroxyurea—brain cancer	0.00116	0.00431	CcSEcCtD
Pomalidomide—CRBN—spinal cord—brain cancer	0.00116	0.0545	CbGeAlD
Pomalidomide—Dehydration—Temozolomide—brain cancer	0.00116	0.00429	CcSEcCtD
Pomalidomide—Anaemia—Procarbazine—brain cancer	0.00115	0.00425	CcSEcCtD
Pomalidomide—Dry skin—Temozolomide—brain cancer	0.00114	0.00423	CcSEcCtD
Pomalidomide—Muscular weakness—Carmustine—brain cancer	0.00114	0.00421	CcSEcCtD
Pomalidomide—Hypokalaemia—Temozolomide—brain cancer	0.00114	0.0042	CcSEcCtD
Pomalidomide—CYP1A2—Xenobiotics—CYP2C9—brain cancer	0.00113	0.0184	CbGpPWpGaD
Pomalidomide—Breast disorder—Temozolomide—brain cancer	0.00113	0.00417	CcSEcCtD
Pomalidomide—Leukopenia—Procarbazine—brain cancer	0.00111	0.00411	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Etoposide—brain cancer	0.0011	0.00407	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Temozolomide—brain cancer	0.0011	0.00407	CcSEcCtD
Pomalidomide—Muscular weakness—Temozolomide—brain cancer	0.0011	0.00407	CcSEcCtD
Pomalidomide—CYP1A2—Tamoxifen metabolism—CYP2C9—brain cancer	0.00109	0.0177	CbGpPWpGaD
Pomalidomide—Cough—Procarbazine—brain cancer	0.00108	0.00401	CcSEcCtD
Pomalidomide—Pancytopenia—Carmustine—brain cancer	0.00106	0.00392	CcSEcCtD
Pomalidomide—Arthralgia—Procarbazine—brain cancer	0.00106	0.00391	CcSEcCtD
Pomalidomide—Anxiety—Procarbazine—brain cancer	0.00105	0.0039	CcSEcCtD
Pomalidomide—CRBN—endocrine gland—brain cancer	0.00105	0.0491	CbGeAlD
Pomalidomide—Neutropenia—Carmustine—brain cancer	0.00104	0.00386	CcSEcCtD
Pomalidomide—Bronchitis—Temozolomide—brain cancer	0.00104	0.00384	CcSEcCtD
Pomalidomide—CRBN—head—brain cancer	0.00103	0.0484	CbGeAlD
Pomalidomide—Pancytopenia—Temozolomide—brain cancer	0.00102	0.00379	CcSEcCtD
Pomalidomide—Confusional state—Procarbazine—brain cancer	0.00102	0.00378	CcSEcCtD
Pomalidomide—Vomiting—Lomustine—brain cancer	0.00102	0.00376	CcSEcCtD
Pomalidomide—PTGS2—endothelium—brain cancer	0.00101	0.0474	CbGeAlD
Pomalidomide—Neutropenia—Temozolomide—brain cancer	0.00101	0.00373	CcSEcCtD
Pomalidomide—Infection—Procarbazine—brain cancer	0.00101	0.00373	CcSEcCtD
Pomalidomide—Hyperglycaemia—Carmustine—brain cancer	0.00101	0.00372	CcSEcCtD
Pomalidomide—Angiopathy—Hydroxyurea—brain cancer	0.001	0.00371	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Temozolomide—brain cancer	0.001	0.00371	CcSEcCtD
Pomalidomide—Pneumonia—Carmustine—brain cancer	0.001	0.0037	CcSEcCtD
Pomalidomide—Thrombocytopenia—Procarbazine—brain cancer	0.000993	0.00367	CcSEcCtD
Pomalidomide—Chills—Hydroxyurea—brain cancer	0.000992	0.00367	CcSEcCtD
Pomalidomide—Weight increased—Temozolomide—brain cancer	0.000982	0.00363	CcSEcCtD
Pomalidomide—Hyperhidrosis—Procarbazine—brain cancer	0.000981	0.00363	CcSEcCtD
Pomalidomide—Renal failure—Carmustine—brain cancer	0.000978	0.00362	CcSEcCtD
Pomalidomide—Weight decreased—Temozolomide—brain cancer	0.000976	0.00361	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Carmustine—brain cancer	0.000976	0.00361	CcSEcCtD
Pomalidomide—Hyperglycaemia—Temozolomide—brain cancer	0.000973	0.0036	CcSEcCtD
Pomalidomide—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000971	0.0159	CbGpPWpGaD
Pomalidomide—Urinary tract infection—Carmustine—brain cancer	0.000968	0.00358	CcSEcCtD
Pomalidomide—Pneumonia—Temozolomide—brain cancer	0.000967	0.00358	CcSEcCtD
Pomalidomide—Infestation—Temozolomide—brain cancer	0.000962	0.00356	CcSEcCtD
Pomalidomide—Infestation NOS—Temozolomide—brain cancer	0.000962	0.00356	CcSEcCtD
Pomalidomide—PTGS2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000959	0.0157	CbGpPWpGaD
Pomalidomide—Nausea—Lomustine—brain cancer	0.000949	0.00351	CcSEcCtD
Pomalidomide—CRBN—central nervous system—brain cancer	0.000944	0.0442	CbGeAlD
Pomalidomide—Neuropathy peripheral—Temozolomide—brain cancer	0.000943	0.00349	CcSEcCtD
Pomalidomide—Urinary tract infection—Temozolomide—brain cancer	0.000935	0.00346	CcSEcCtD
Pomalidomide—PTGS2—blood vessel—brain cancer	0.000932	0.0437	CbGeAlD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000925	0.0151	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000924	0.00342	CcSEcCtD
Pomalidomide—CRBN—cerebellum—brain cancer	0.000923	0.0432	CbGeAlD
Pomalidomide—Insomnia—Procarbazine—brain cancer	0.000918	0.00339	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Temozolomide—brain cancer	0.00091	0.00336	CcSEcCtD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—IRS2—brain cancer	0.000897	0.0147	CbGpPWpGaD
Pomalidomide—Anaemia—Hydroxyurea—brain cancer	0.000889	0.00329	CcSEcCtD
Pomalidomide—Decreased appetite—Procarbazine—brain cancer	0.000882	0.00326	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Etoposide—brain cancer	0.000881	0.00326	CcSEcCtD
Pomalidomide—Oedema peripheral—Carmustine—brain cancer	0.00088	0.00325	CcSEcCtD
Pomalidomide—Connective tissue disorder—Carmustine—brain cancer	0.000878	0.00325	CcSEcCtD
Pomalidomide—Fatigue—Procarbazine—brain cancer	0.000875	0.00323	CcSEcCtD
Pomalidomide—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.000871	0.0142	CbGpPWpGaD
Pomalidomide—Constipation—Procarbazine—brain cancer	0.000868	0.00321	CcSEcCtD
Pomalidomide—Pain—Procarbazine—brain cancer	0.000868	0.00321	CcSEcCtD
Pomalidomide—Leukopenia—Hydroxyurea—brain cancer	0.000861	0.00318	CcSEcCtD
Pomalidomide—Urinary tract disorder—Temozolomide—brain cancer	0.000853	0.00315	CcSEcCtD
Pomalidomide—Oedema peripheral—Temozolomide—brain cancer	0.000851	0.00315	CcSEcCtD
Pomalidomide—Connective tissue disorder—Temozolomide—brain cancer	0.000849	0.00314	CcSEcCtD
Pomalidomide—Urethral disorder—Temozolomide—brain cancer	0.000846	0.00313	CcSEcCtD
Pomalidomide—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000838	0.0137	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Procarbazine—brain cancer	0.000836	0.00309	CcSEcCtD
Pomalidomide—Pancytopenia—Etoposide—brain cancer	0.00082	0.00303	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000814	0.00301	CcSEcCtD
Pomalidomide—Neutropenia—Etoposide—brain cancer	0.000807	0.00298	CcSEcCtD
Pomalidomide—Body temperature increased—Procarbazine—brain cancer	0.000802	0.00297	CcSEcCtD
Pomalidomide—Cardiac disorder—Temozolomide—brain cancer	0.000801	0.00296	CcSEcCtD
Pomalidomide—Angiopathy—Temozolomide—brain cancer	0.000783	0.0029	CcSEcCtD
Pomalidomide—Mental disorder—Carmustine—brain cancer	0.000783	0.00289	CcSEcCtD
Pomalidomide—Infection—Hydroxyurea—brain cancer	0.00078	0.00288	CcSEcCtD
Pomalidomide—Mediastinal disorder—Temozolomide—brain cancer	0.000778	0.00288	CcSEcCtD
Pomalidomide—Malnutrition—Carmustine—brain cancer	0.000778	0.00288	CcSEcCtD
Pomalidomide—Chills—Temozolomide—brain cancer	0.000775	0.00286	CcSEcCtD
Pomalidomide—Pneumonia—Etoposide—brain cancer	0.000774	0.00286	CcSEcCtD
Pomalidomide—Nervous system disorder—Hydroxyurea—brain cancer	0.00077	0.00285	CcSEcCtD
Pomalidomide—Infestation NOS—Etoposide—brain cancer	0.00077	0.00285	CcSEcCtD
Pomalidomide—Infestation—Etoposide—brain cancer	0.00077	0.00285	CcSEcCtD
Pomalidomide—Thrombocytopenia—Hydroxyurea—brain cancer	0.000769	0.00284	CcSEcCtD
Pomalidomide—Skin disorder—Hydroxyurea—brain cancer	0.000763	0.00282	CcSEcCtD
Pomalidomide—Renal failure—Etoposide—brain cancer	0.000757	0.0028	CcSEcCtD
Pomalidomide—Mental disorder—Temozolomide—brain cancer	0.000757	0.0028	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Etoposide—brain cancer	0.000754	0.00279	CcSEcCtD
Pomalidomide—Back pain—Carmustine—brain cancer	0.000752	0.00278	CcSEcCtD
Pomalidomide—Malnutrition—Temozolomide—brain cancer	0.000752	0.00278	CcSEcCtD
Pomalidomide—CRBN—brain—brain cancer	0.00075	0.0351	CbGeAlD
Pomalidomide—Hypersensitivity—Procarbazine—brain cancer	0.000748	0.00276	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000739	0.0121	CbGpPWpGaD
Pomalidomide—Tremor—Carmustine—brain cancer	0.000729	0.00269	CcSEcCtD
Pomalidomide—Asthenia—Procarbazine—brain cancer	0.000728	0.00269	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Etoposide—brain cancer	0.000728	0.00269	CcSEcCtD
Pomalidomide—Back pain—Temozolomide—brain cancer	0.000727	0.00269	CcSEcCtD
Pomalidomide—Anaemia—Carmustine—brain cancer	0.000719	0.00266	CcSEcCtD
Pomalidomide—Pruritus—Procarbazine—brain cancer	0.000718	0.00265	CcSEcCtD
Pomalidomide—Tremor—Temozolomide—brain cancer	0.000704	0.0026	CcSEcCtD
Pomalidomide—Dyspnoea—Hydroxyurea—brain cancer	0.0007	0.00259	CcSEcCtD
Pomalidomide—Leukopenia—Carmustine—brain cancer	0.000696	0.00257	CcSEcCtD
Pomalidomide—Anaemia—Temozolomide—brain cancer	0.000695	0.00257	CcSEcCtD
Pomalidomide—Diarrhoea—Procarbazine—brain cancer	0.000694	0.00257	CcSEcCtD
Pomalidomide—Decreased appetite—Hydroxyurea—brain cancer	0.000683	0.00252	CcSEcCtD
Pomalidomide—Urinary tract disorder—Etoposide—brain cancer	0.000682	0.00252	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000678	0.00251	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—HES5—brain cancer	0.000678	0.0111	CbGpPWpGaD
Pomalidomide—Urethral disorder—Etoposide—brain cancer	0.000677	0.0025	CcSEcCtD
Pomalidomide—Fatigue—Hydroxyurea—brain cancer	0.000677	0.0025	CcSEcCtD
Pomalidomide—Vertigo—Temozolomide—brain cancer	0.000675	0.0025	CcSEcCtD
Pomalidomide—Leukopenia—Temozolomide—brain cancer	0.000673	0.00249	CcSEcCtD
Pomalidomide—Pain—Hydroxyurea—brain cancer	0.000672	0.00248	CcSEcCtD
Pomalidomide—Constipation—Hydroxyurea—brain cancer	0.000672	0.00248	CcSEcCtD
Pomalidomide—Dizziness—Procarbazine—brain cancer	0.000671	0.00248	CcSEcCtD
Pomalidomide—Anxiety—Carmustine—brain cancer	0.00066	0.00244	CcSEcCtD
Pomalidomide—Cough—Temozolomide—brain cancer	0.000656	0.00243	CcSEcCtD
Pomalidomide—Feeling abnormal—Hydroxyurea—brain cancer	0.000647	0.00239	CcSEcCtD
Pomalidomide—Vomiting—Procarbazine—brain cancer	0.000645	0.00239	CcSEcCtD
Pomalidomide—Cardiac disorder—Etoposide—brain cancer	0.000641	0.00237	CcSEcCtD
Pomalidomide—Confusional state—Carmustine—brain cancer	0.00064	0.00237	CcSEcCtD
Pomalidomide—Arthralgia—Temozolomide—brain cancer	0.00064	0.00237	CcSEcCtD
Pomalidomide—Rash—Procarbazine—brain cancer	0.00064	0.00237	CcSEcCtD
Pomalidomide—Dermatitis—Procarbazine—brain cancer	0.000639	0.00236	CcSEcCtD
Pomalidomide—Anxiety—Temozolomide—brain cancer	0.000638	0.00236	CcSEcCtD
Pomalidomide—Headache—Procarbazine—brain cancer	0.000636	0.00235	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000636	0.00235	CcSEcCtD
Pomalidomide—Infection—Carmustine—brain cancer	0.000631	0.00233	CcSEcCtD
Pomalidomide—Angiopathy—Etoposide—brain cancer	0.000627	0.00232	CcSEcCtD
Pomalidomide—Mediastinal disorder—Etoposide—brain cancer	0.000623	0.0023	CcSEcCtD
Pomalidomide—Thrombocytopenia—Carmustine—brain cancer	0.000622	0.0023	CcSEcCtD
Pomalidomide—Body temperature increased—Hydroxyurea—brain cancer	0.000621	0.0023	CcSEcCtD
Pomalidomide—Chills—Etoposide—brain cancer	0.00062	0.00229	CcSEcCtD
Pomalidomide—Confusional state—Temozolomide—brain cancer	0.000619	0.00229	CcSEcCtD
Pomalidomide—Infection—Temozolomide—brain cancer	0.000609	0.00225	CcSEcCtD
Pomalidomide—Nausea—Procarbazine—brain cancer	0.000603	0.00223	CcSEcCtD
Pomalidomide—Nervous system disorder—Temozolomide—brain cancer	0.000602	0.00222	CcSEcCtD
Pomalidomide—Thrombocytopenia—Temozolomide—brain cancer	0.000601	0.00222	CcSEcCtD
Pomalidomide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000598	0.00977	CbGpPWpGaD
Pomalidomide—TNF—EBV LMP1 signaling—RELA—brain cancer	0.000598	0.00976	CbGpPWpGaD
Pomalidomide—TNF—Canonical NF-kappaB pathway—RELA—brain cancer	0.000598	0.00976	CbGpPWpGaD
Pomalidomide—Skin disorder—Temozolomide—brain cancer	0.000596	0.0022	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000595	0.00972	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Temozolomide—brain cancer	0.000593	0.00219	CcSEcCtD
Pomalidomide—Back pain—Etoposide—brain cancer	0.000582	0.00215	CcSEcCtD
Pomalidomide—Hypersensitivity—Hydroxyurea—brain cancer	0.000579	0.00214	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Carmustine—brain cancer	0.000578	0.00214	CcSEcCtD
Pomalidomide—Muscle spasms—Etoposide—brain cancer	0.000578	0.00214	CcSEcCtD
Pomalidomide—ABCB1—blood vessel—brain cancer	0.000577	0.027	CbGeAlD
Pomalidomide—Insomnia—Carmustine—brain cancer	0.000574	0.00212	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—GFAP—brain cancer	0.00057	0.00931	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00057	0.00931	CbGpPWpGaD
Pomalidomide—Dyspnoea—Carmustine—brain cancer	0.000566	0.00209	CcSEcCtD
Pomalidomide—Asthenia—Hydroxyurea—brain cancer	0.000563	0.00208	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000559	0.00207	CcSEcCtD
Pomalidomide—Anaemia—Etoposide—brain cancer	0.000556	0.00206	CcSEcCtD
Pomalidomide—Insomnia—Temozolomide—brain cancer	0.000555	0.00205	CcSEcCtD
Pomalidomide—Decreased appetite—Carmustine—brain cancer	0.000552	0.00204	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Carmustine—brain cancer	0.000548	0.00203	CcSEcCtD
Pomalidomide—Dyspnoea—Temozolomide—brain cancer	0.000547	0.00202	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—SOD2—brain cancer	0.000547	0.00893	CbGpPWpGaD
Pomalidomide—Constipation—Carmustine—brain cancer	0.000543	0.00201	CcSEcCtD
Pomalidomide—Pain—Carmustine—brain cancer	0.000543	0.00201	CcSEcCtD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000542	0.00886	CbGpPWpGaD
Pomalidomide—Vertigo—Etoposide—brain cancer	0.00054	0.002	CcSEcCtD
Pomalidomide—Leukopenia—Etoposide—brain cancer	0.000538	0.00199	CcSEcCtD
Pomalidomide—Diarrhoea—Hydroxyurea—brain cancer	0.000537	0.00199	CcSEcCtD
Pomalidomide—Decreased appetite—Temozolomide—brain cancer	0.000533	0.00197	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Temozolomide—brain cancer	0.00053	0.00196	CcSEcCtD
Pomalidomide—Fatigue—Temozolomide—brain cancer	0.000529	0.00196	CcSEcCtD
Pomalidomide—Cough—Etoposide—brain cancer	0.000525	0.00194	CcSEcCtD
Pomalidomide—Pain—Temozolomide—brain cancer	0.000525	0.00194	CcSEcCtD
Pomalidomide—Constipation—Temozolomide—brain cancer	0.000525	0.00194	CcSEcCtD
Pomalidomide—Feeling abnormal—Carmustine—brain cancer	0.000523	0.00193	CcSEcCtD
Pomalidomide—Dizziness—Hydroxyurea—brain cancer	0.000519	0.00192	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000509	0.00188	CcSEcCtD
Pomalidomide—Feeling abnormal—Temozolomide—brain cancer	0.000506	0.00187	CcSEcCtD
Pomalidomide—Body temperature increased—Carmustine—brain cancer	0.000502	0.00186	CcSEcCtD
Pomalidomide—Vomiting—Hydroxyurea—brain cancer	0.000499	0.00185	CcSEcCtD
Pomalidomide—Rash—Hydroxyurea—brain cancer	0.000495	0.00183	CcSEcCtD
Pomalidomide—Confusional state—Etoposide—brain cancer	0.000495	0.00183	CcSEcCtD
Pomalidomide—Dermatitis—Hydroxyurea—brain cancer	0.000495	0.00183	CcSEcCtD
Pomalidomide—Headache—Hydroxyurea—brain cancer	0.000492	0.00182	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—IL2—brain cancer	0.000488	0.00797	CbGpPWpGaD
Pomalidomide—Infection—Etoposide—brain cancer	0.000488	0.0018	CcSEcCtD
Pomalidomide—TNF—Apoptosis—DAPK1—brain cancer	0.000488	0.00796	CbGpPWpGaD
Pomalidomide—Body temperature increased—Temozolomide—brain cancer	0.000485	0.00179	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—SPP1—brain cancer	0.000484	0.0079	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Etoposide—brain cancer	0.000481	0.00178	CcSEcCtD
Pomalidomide—Skin disorder—Etoposide—brain cancer	0.000477	0.00176	CcSEcCtD
Pomalidomide—Hyperhidrosis—Etoposide—brain cancer	0.000475	0.00175	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL2—brain cancer	0.000473	0.00773	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000469	0.00766	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Carmustine—brain cancer	0.000468	0.00173	CcSEcCtD
Pomalidomide—Nausea—Hydroxyurea—brain cancer	0.000466	0.00172	CcSEcCtD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000463	0.00755	CbGpPWpGaD
Pomalidomide—Asthenia—Carmustine—brain cancer	0.000455	0.00168	CcSEcCtD
Pomalidomide—PTGS2—telencephalon—brain cancer	0.000452	0.0212	CbGeAlD
Pomalidomide—Hypersensitivity—Temozolomide—brain cancer	0.000452	0.00167	CcSEcCtD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—RELA—brain cancer	0.000448	0.00731	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—SOD2—brain cancer	0.000445	0.00726	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—SIRT1—brain cancer	0.000441	0.0072	CbGpPWpGaD
Pomalidomide—Asthenia—Temozolomide—brain cancer	0.00044	0.00163	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—brain cancer	0.000438	0.00162	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—brain cancer	0.000437	0.00713	CbGpPWpGaD
Pomalidomide—Diarrhoea—Carmustine—brain cancer	0.000434	0.00161	CcSEcCtD
Pomalidomide—Pruritus—Temozolomide—brain cancer	0.000434	0.0016	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—brain cancer	0.000427	0.00158	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—brain cancer	0.000424	0.00157	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—brain cancer	0.000423	0.00156	CcSEcCtD
Pomalidomide—Dizziness—Carmustine—brain cancer	0.00042	0.00155	CcSEcCtD
Pomalidomide—Constipation—Etoposide—brain cancer	0.00042	0.00155	CcSEcCtD
Pomalidomide—Pain—Etoposide—brain cancer	0.00042	0.00155	CcSEcCtD
Pomalidomide—Diarrhoea—Temozolomide—brain cancer	0.00042	0.00155	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—STAT3—brain cancer	0.000411	0.0067	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—RELA—brain cancer	0.000409	0.00667	CbGpPWpGaD
Pomalidomide—Dizziness—Temozolomide—brain cancer	0.000406	0.0015	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—brain cancer	0.000405	0.0015	CcSEcCtD
Pomalidomide—Vomiting—Carmustine—brain cancer	0.000404	0.00149	CcSEcCtD
Pomalidomide—Rash—Carmustine—brain cancer	0.0004	0.00148	CcSEcCtD
Pomalidomide—Dermatitis—Carmustine—brain cancer	0.0004	0.00148	CcSEcCtD
Pomalidomide—Headache—Carmustine—brain cancer	0.000398	0.00147	CcSEcCtD
Pomalidomide—Vomiting—Temozolomide—brain cancer	0.00039	0.00144	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—brain cancer	0.000388	0.00143	CcSEcCtD
Pomalidomide—Rash—Temozolomide—brain cancer	0.000387	0.00143	CcSEcCtD
Pomalidomide—Dermatitis—Temozolomide—brain cancer	0.000386	0.00143	CcSEcCtD
Pomalidomide—Headache—Temozolomide—brain cancer	0.000384	0.00142	CcSEcCtD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00038	0.00621	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000378	0.00618	CbGpPWpGaD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—brain cancer	0.000378	0.00618	CbGpPWpGaD
Pomalidomide—Nausea—Carmustine—brain cancer	0.000377	0.00139	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—RELA—brain cancer	0.000369	0.00603	CbGpPWpGaD
Pomalidomide—PTGS2—pituitary gland—brain cancer	0.000368	0.0172	CbGeAlD
Pomalidomide—TNF—IL23-mediated signaling events—IL2—brain cancer	0.000368	0.00601	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—PDGFRA—brain cancer	0.000368	0.006	CbGpPWpGaD
Pomalidomide—Nausea—Temozolomide—brain cancer	0.000364	0.00135	CcSEcCtD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000362	0.00591	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Etoposide—brain cancer	0.000362	0.00134	CcSEcCtD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000357	0.00583	CbGpPWpGaD
Pomalidomide—PTGS2—medulla oblongata—brain cancer	0.000355	0.0166	CbGeAlD
Pomalidomide—TNF—Selenium Micronutrient Network—SOD2—brain cancer	0.000353	0.00577	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—GFAP—brain cancer	0.000353	0.00576	CbGpPWpGaD
Pomalidomide—Asthenia—Etoposide—brain cancer	0.000352	0.0013	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—brain cancer	0.000347	0.00128	CcSEcCtD
Pomalidomide—CYP1A2—endocrine gland—brain cancer	0.000344	0.0161	CbGeAlD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—RELA—brain cancer	0.000343	0.0056	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —RELA—brain cancer	0.000343	0.0056	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000337	0.00551	CbGpPWpGaD
Pomalidomide—Diarrhoea—Etoposide—brain cancer	0.000336	0.00124	CcSEcCtD
Pomalidomide—TNF—Ceramide signaling pathway—RELA—brain cancer	0.000332	0.00542	CbGpPWpGaD
Pomalidomide—PTGS2—S1P1 pathway—VEGFA—brain cancer	0.00033	0.00538	CbGpPWpGaD
Pomalidomide—PTGS2—midbrain—brain cancer	0.000325	0.0152	CbGeAlD
Pomalidomide—Dizziness—Etoposide—brain cancer	0.000325	0.0012	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—RELA—brain cancer	0.000321	0.00524	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CTNNB1—brain cancer	0.000321	0.00524	CbGpPWpGaD
Pomalidomide—PTGS2—spinal cord—brain cancer	0.000317	0.0148	CbGeAlD
Pomalidomide—TNF—Vitamin B12 Metabolism—RELA—brain cancer	0.000316	0.00516	CbGpPWpGaD
Pomalidomide—Vomiting—Etoposide—brain cancer	0.000312	0.00115	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—STAT3—brain cancer	0.00031	0.00506	CbGpPWpGaD
Pomalidomide—Rash—Etoposide—brain cancer	0.00031	0.00114	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—brain cancer	0.000309	0.00114	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	0.000309	0.00505	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDK6—brain cancer	0.000309	0.00505	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—CDK4—brain cancer	0.000309	0.00505	CbGpPWpGaD
Pomalidomide—Headache—Etoposide—brain cancer	0.000308	0.00114	CcSEcCtD
Pomalidomide—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000307	0.00502	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000307	0.00501	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000293	0.00479	CbGpPWpGaD
Pomalidomide—Nausea—Etoposide—brain cancer	0.000292	0.00108	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—SPP1—brain cancer	0.000291	0.00475	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000291	0.00475	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—brain cancer	0.000289	0.00472	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—ESR2—brain cancer	0.000288	0.00471	CbGpPWpGaD
Pomalidomide—PTGS2—endocrine gland—brain cancer	0.000285	0.0134	CbGeAlD
Pomalidomide—PTGS2—head—brain cancer	0.000282	0.0132	CbGeAlD
Pomalidomide—ABCB1—telencephalon—brain cancer	0.00028	0.0131	CbGeAlD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—brain cancer	0.000277	0.00452	CbGpPWpGaD
Pomalidomide—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.000273	0.00445	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—PIK3CG—brain cancer	0.000271	0.00443	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—brain cancer	0.00027	0.00441	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	0.000263	0.00429	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—CTNNB1—brain cancer	0.000263	0.00429	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—RELA—brain cancer	0.000257	0.0042	CbGpPWpGaD
Pomalidomide—PTGS2—central nervous system—brain cancer	0.000257	0.012	CbGeAlD
Pomalidomide—PTGS2—cerebellum—brain cancer	0.000251	0.0118	CbGeAlD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—STAT3—brain cancer	0.00025	0.00409	CbGpPWpGaD
Pomalidomide—CYP3A4—endocrine gland—brain cancer	0.000249	0.0117	CbGeAlD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000245	0.00401	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—RELA—brain cancer	0.000245	0.00401	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—MYC—brain cancer	0.000242	0.00395	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	0.000236	0.00386	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EGFR—brain cancer	0.000236	0.00386	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000236	0.00386	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—MYC—brain cancer	0.000234	0.00381	CbGpPWpGaD
Pomalidomide—ABCB1—gonad—brain cancer	0.000233	0.0109	CbGeAlD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—PIK3CG—brain cancer	0.000232	0.00379	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL2—brain cancer	0.000232	0.00378	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—brain cancer	0.000232	0.00378	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—brain cancer	0.000231	0.00378	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—STAT3—brain cancer	0.000229	0.00374	CbGpPWpGaD
Pomalidomide—ABCB1—pituitary gland—brain cancer	0.000228	0.0107	CbGeAlD
Pomalidomide—PTGS2—C-MYB transcription factor network—HES1—brain cancer	0.000227	0.00371	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—RELA—brain cancer	0.000227	0.00371	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—SPP1—brain cancer	0.000227	0.00371	CbGpPWpGaD
Pomalidomide—CYP3A4—central nervous system—brain cancer	0.000225	0.0105	CbGeAlD
Pomalidomide—TNF—SIDS Susceptibility Pathways—HES1—brain cancer	0.000224	0.00366	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CDKN2A—brain cancer	0.00022	0.0036	CbGpPWpGaD
Pomalidomide—ABCB1—medulla oblongata—brain cancer	0.00022	0.0103	CbGeAlD
Pomalidomide—TNF—Spinal Cord Injury—CDK4—brain cancer	0.00022	0.00359	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—SOD2—brain cancer	0.000219	0.00357	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IRS2—brain cancer	0.000217	0.00354	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—RELA—brain cancer	0.000212	0.00347	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—RELA—brain cancer	0.000212	0.00346	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000208	0.0034	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—RELA—brain cancer	0.000204	0.00334	CbGpPWpGaD
Pomalidomide—PTGS2—brain—brain cancer	0.000204	0.00956	CbGeAlD
Pomalidomide—CYP1A2—Biological oxidations—CYP2C9—brain cancer	0.000202	0.0033	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.000201	0.00329	CbGpPWpGaD
Pomalidomide—ABCB1—midbrain—brain cancer	0.000201	0.00941	CbGeAlD
Pomalidomide—TNF—Allograft Rejection—IL2—brain cancer	0.000201	0.00327	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	0.000199	0.00325	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.000198	0.00323	CbGpPWpGaD
Pomalidomide—ABCB1—spinal cord—brain cancer	0.000196	0.00918	CbGeAlD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.000195	0.00319	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.00019	0.0031	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—STAT3—brain cancer	0.000186	0.00304	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—brain cancer	0.000184	0.00301	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—RELA—brain cancer	0.000182	0.00296	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.000181	0.00296	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—PIK3CG—brain cancer	0.000181	0.00296	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.00018	0.00294	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—brain cancer	0.000179	0.00292	CbGpPWpGaD
Pomalidomide—ABCB1—endocrine gland—brain cancer	0.000176	0.00827	CbGeAlD
Pomalidomide—ABCB1—head—brain cancer	0.000174	0.00816	CbGeAlD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	0.000173	0.00282	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—VEGFA—brain cancer	0.00017	0.00278	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—APC—brain cancer	0.000166	0.00271	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	0.000162	0.00265	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—PDGFRA—brain cancer	0.000161	0.00263	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—brain cancer	0.000161	0.00262	CbGpPWpGaD
Pomalidomide—ABCB1—central nervous system—brain cancer	0.000159	0.00745	CbGeAlD
Pomalidomide—CYP3A4—Biological oxidations—CYP2C9—brain cancer	0.000156	0.00254	CbGpPWpGaD
Pomalidomide—ABCB1—cerebellum—brain cancer	0.000155	0.00728	CbGeAlD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	0.000154	0.00251	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—brain cancer	0.000153	0.00249	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000152	0.00248	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—brain cancer	0.000149	0.00244	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	0.000149	0.00244	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MYC—brain cancer	0.000149	0.00244	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—brain cancer	0.000149	0.00243	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	0.000146	0.00239	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—brain cancer	0.000145	0.00238	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CCND1—brain cancer	0.000142	0.00232	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—RELA—brain cancer	0.000142	0.00231	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—APC—brain cancer	0.000141	0.0023	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TRPC6—brain cancer	0.000138	0.00226	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000137	0.00224	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—brain cancer	0.000136	0.00222	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDK4—brain cancer	0.000136	0.00222	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000134	0.00219	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CTNNB1—brain cancer	0.00013	0.00212	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—brain cancer	0.000129	0.0021	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000127	0.00208	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—RELA—brain cancer	0.000126	0.00206	CbGpPWpGaD
Pomalidomide—ABCB1—brain—brain cancer	0.000126	0.00591	CbGeAlD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.000125	0.00203	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—brain cancer	0.000123	0.002	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.000122	0.002	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.000121	0.00197	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	0.00012	0.00196	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CCND1—brain cancer	0.000115	0.00188	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—brain cancer	0.000114	0.00186	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—STAT3—brain cancer	0.000113	0.00185	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CTNNB1—brain cancer	0.000113	0.00184	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—brain cancer	0.000112	0.00183	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.000112	0.00183	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000111	0.00182	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—brain cancer	0.000111	0.00182	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	0.000109	0.00178	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	0.000108	0.00177	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—DTX2—brain cancer	0.000108	0.00176	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000108	0.00176	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	0.000107	0.00175	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	0.000101	0.00165	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.0001	0.00164	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—brain cancer	9.89e-05	0.00161	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	9.65e-05	0.00158	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	9.56e-05	0.00156	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—brain cancer	9.34e-05	0.00153	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	9.24e-05	0.00151	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—brain cancer	9.23e-05	0.00151	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	9.2e-05	0.0015	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—brain cancer	9e-05	0.00147	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HES1—brain cancer	8.91e-05	0.00145	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	8.83e-05	0.00144	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—brain cancer	8.79e-05	0.00144	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—brain cancer	8.77e-05	0.00143	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—brain cancer	8.7e-05	0.00142	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	8.66e-05	0.00141	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	8.63e-05	0.00141	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—brain cancer	8.58e-05	0.0014	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	8.55e-05	0.0014	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	8.46e-05	0.00138	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	8.41e-05	0.00137	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—brain cancer	8.39e-05	0.00137	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	8.27e-05	0.00135	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	8.27e-05	0.00135	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	7.95e-05	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HES5—brain cancer	7.92e-05	0.00129	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	7.75e-05	0.00127	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	7.74e-05	0.00126	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	7.58e-05	0.00124	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	7.57e-05	0.00124	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—brain cancer	7.51e-05	0.00123	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—brain cancer	7.47e-05	0.00122	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—brain cancer	7.04e-05	0.00115	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—brain cancer	7.04e-05	0.00115	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CDK4—brain cancer	6.99e-05	0.00114	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—brain cancer	6.88e-05	0.00112	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	6.75e-05	0.0011	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	6.55e-05	0.00107	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	6.36e-05	0.00104	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	6.17e-05	0.00101	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP2C9—brain cancer	6.1e-05	0.000996	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	5.97e-05	0.000974	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	5.91e-05	0.000965	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—brain cancer	5.78e-05	0.000943	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	5.67e-05	0.000926	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IDH1—brain cancer	5.33e-05	0.00087	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	5.2e-05	0.000849	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—BSG—brain cancer	5.19e-05	0.000847	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	5.15e-05	0.00084	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—RELA—brain cancer	5.14e-05	0.000839	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ERBB2—brain cancer	5.11e-05	0.000834	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HEY1—brain cancer	5.05e-05	0.000825	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—DLL1—brain cancer	4.95e-05	0.000809	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	4.79e-05	0.000782	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	4.79e-05	0.000782	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	4.68e-05	0.000764	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—brain cancer	4.47e-05	0.000729	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—IDH1—brain cancer	4.46e-05	0.000728	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2C9—brain cancer	4.32e-05	0.000706	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	4.23e-05	0.000691	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ENO2—brain cancer	4.21e-05	0.000688	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SHH—brain cancer	4.21e-05	0.000688	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	4.19e-05	0.000684	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—brain cancer	3.93e-05	0.000642	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	3.93e-05	0.000642	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—brain cancer	3.89e-05	0.000636	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	3.69e-05	0.000602	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—BSG—brain cancer	3.68e-05	0.0006	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.63e-05	0.000593	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—brain cancer	3.54e-05	0.000578	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ENO2—brain cancer	3.53e-05	0.000576	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2C9—brain cancer	3.45e-05	0.000564	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	3.39e-05	0.000554	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	3.32e-05	0.000542	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—IDH1—brain cancer	3.16e-05	0.000516	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—VAV1—brain cancer	3.04e-05	0.000497	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—BSG—brain cancer	2.94e-05	0.000479	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	2.79e-05	0.000455	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2C9—brain cancer	2.66e-05	0.000435	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HES1—brain cancer	2.62e-05	0.000427	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—IDH1—brain cancer	2.52e-05	0.000412	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO2—brain cancer	2.5e-05	0.000408	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFRA—brain cancer	2.49e-05	0.000407	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—BSG—brain cancer	2.27e-05	0.00037	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IRS2—brain cancer	2.19e-05	0.000357	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.06e-05	0.000336	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO2—brain cancer	2e-05	0.000326	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—IDH1—brain cancer	1.95e-05	0.000318	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APC—brain cancer	1.93e-05	0.000315	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CG—brain cancer	1.62e-05	0.000264	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO2—brain cancer	1.54e-05	0.000251	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—brain cancer	1.5e-05	0.000245	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—brain cancer	1.31e-05	0.000214	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CG—brain cancer	1.15e-05	0.000187	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—brain cancer	1.14e-05	0.000187	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—brain cancer	1.06e-05	0.000174	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—brain cancer	1.04e-05	0.00017	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CG—brain cancer	9.15e-06	0.000149	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CG—brain cancer	7.07e-06	0.000115	CbGpPWpGaD
